Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotricityBTCY -0.18%20 FCF Margin % is -0.49% as of Mar. 2026. GuruFocus rates BTCY with a GF Score™ of 20/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Biotricity ranks worse than 57.91% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biotricity's Free Cash Flow for the
three
months ended in Mar. 2026 was $-0.02 Mil. Biotricity's Revenue for the
three
months ended in Mar. 2026 was $4.25 Mil. Therefore, Biotricity's FCF Margin % for the quarter that ended in Mar. 2026 was -0.49%.
The historical rank and industry rank for Biotricity's FCF Margin % or its related term are showing as below:
BTCY'
s FCF Margin % Range Over the Past 10 Years
Min: -1311.81 Med: -169.58 Max: -4.49
Current: -4.49
During the past 13 years, the highest FCF Margin % of Biotricity was -4.49%. The lowest was -1311.81%. And the median was -169.58%.
BTCY's FCF Margin % is ranked worse than 57.91% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.56
vs BTCY: -4.49
Biotricity FCF Margin % Related Terms
Biotricity FCF Margin % Historical Data
* Premium members only.
The historical data trend for Biotricity's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biotricity's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotricity FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biotricity's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotricity (BTCY) has a FCF Margin % of -0.49% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biotricity and its competitors. According to the industry distribution chart, Biotricity ranks #472 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 57.9%.
Is Biotricity's FCF Margin % too high?
Biotricity's current FCF Margin % is -0.49%. Based on the distribution chart, Biotricity ranks #472 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biotricity has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotricity's FCF Margin % compare to FEED and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Biotricity ranks #472 out of 815 companies for FCF Margin %. This places Biotricity in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biotricity and its competitors. Biotricity's current FCF Margin % is -0.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.11 — trading 71.1% below its estimated fair value. The current FCF Margin % is -0.49%. Biotricity's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biotricity (BTCY), the current FCF Margin % is -0.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotricity (BTCY) Overvalued in 2026?
Based on GuruFocus' analysis, Biotricity stock appears to be undervalued.
The current stock price of $0.11 is trading 71.1% below its estimated GF Value™ of $0.39.
GuruFocus considers Biotricity to be Possible Value Trap.
Key valuation signals for BTCY:
FCF Margin %: -0.49%
GF Value™: $0.39 vs. price of $0.11 (71.1% below fair value)
No single metric tells the full story. See the BTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
20GF Score
Get the complete analysis for BTCY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTCY has been successfully added to your 
